Immunotherapy is distinct from traditional chemotherapy in that it acts on immune cells rather than cancer cells themselves. Monoclonal antibodies targeting immune checkpoints on T cells – CTLA‐4 and PD‐1 – and PD‐L1 on the cells of immune microenvironment are now approved for clinical use in several solid tumors and hematological malignancies. This article provides a general overview of the use of checkpoint inhibitors in hematologic malignancies with a special focus in acute myeloid leukemia.

中文翻译：

---

AML 中的检查点抑制剂：我们到了吗？

免疫疗法与传统化学疗法的不同之处在于它作用于免疫细胞而不是癌细胞本身。针对 T 细胞免疫检查点的单克隆抗体（CTLA-4 和 PD-1）和免疫微环境细胞上的 PD-L1 现已获批用于多种实体瘤和血液恶性肿瘤的临床治疗。本文概述了检查点抑制剂在血液系统恶性肿瘤中的使用，特别关注急性髓性白血病。